Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus bronchial artery embolization in advanced squamous NSCLC after first-line progression
ChiCTR2500105752Phase 2Not yet recruiting
- Sponsor
- Lishui City Central Hospital
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in Pulmonary squamous cell carcinoma, sponsored by Lishui City Central Hospital. Primary endpoint: Objective Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
docetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500105752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105752.